Marco Massari to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Marco Massari has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.278
-
Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS One. 2021; 16(2):e0247275.
Score: 0.047
-
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 01 01; 181(1):24-31.
Score: 0.047
-
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020 10 21; 18(1):405.
Score: 0.046
-
TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. Contemp Clin Trials. 2020 11; 98:106165.
Score: 0.046
-
Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020 09 29; 24(1):589.
Score: 0.046
-
Tocilizumab in Treatment for Patients With COVID-19-Reply. JAMA Intern Med. 2021 07 01; 181(7):1019-1020.
Score: 0.012
-
Methylprednisolone as rescue therapy after tocilizumab failure in patients with severe COVID-19 pneumonia. Clin Exp Rheumatol. 2021 Sep-Oct; 39(5):1141.
Score: 0.012
-
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia. Clin Exp Rheumatol. 2020 Nov-Dec; 38(6):1215-1222.
Score: 0.012
-
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis. 2020 07; 79(7):986-988.
Score: 0.011